• Species Reactivity
  Mouse
• Specificity
  Detects mouse SEZ6/BSRP-C in direct ELISAs and Western blots. In direct ELISAs and Western blots, less than 10% cross-reactivity with recombinant mouse (rm) BSRP-A and rmBSRP-B is observed.
• Source
  Polyclonal Sheep IgG
• Purification
  Antigen Affinity-purified
• Immunogen
  Mouse myeloma cell line NS0-derived recombinant mouse SEZ6/BSRP-C
  Gly19-Asn902
  Accession # Q7TSK2
• Formulation
  Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
• Label
  Unconjugated

• Western Blot
  0.1 µg/mL
  Recombinant Mouse SEZ6/BSRP-C
• Immunohistochemistry
  5-15 µg/mL
  See below

• Reconstitution
  Reconstitute at 0.2 mg/mL in sterile PBS.
• Shipping
  The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
• Stability & Storage
  Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

• Long Name:
  Seizure Related 6/Brain-specific Receptor-like Protein-C
• Entrez Gene IDs:
  124925 (Human); 20370 (Mouse); 192247 (Rat)
• Alternate Names:
  BSRPC; BSRP-C; hSEZ-6; seizure related 6 homolog (mouse); SEZ6

Background:

SEZ6 (Seizure protein 6, also BSRP-C, Brain-specific receptor-like protein C) is a 150 kDa member of the BSRP family of proteins. It is expressed on neurons and exerts an antibranching effect relative to neurite extension. Mature mouse SEZ6 is a 974 amino acid (aa) type I transmembrane glycoprotein. It contains an extracellular domain (ECD) of at least 876 amino acids (aa 18‑893). The ECD shows three CUB domains and five short consensus repeats (SCRs). There are two splice variants for SEZ6. One is soluble, and shows an 18 aa substitution for aa 588‑991, while a second shows a deletion of aa 895‑907 plus a 9 aa substitution for aa 982‑991. Over aa 19‑902, mouse SEZ6 is 91% aa identical to human SEZ6.

      R&D Systems位于美国的明尼苏达州，一直致力于生物制品的开发与生产。公司成立之初主要生产用于医院及临床应用的血控品。1997年，公司推出第一个产品--富血小板血浆质控品；1981年，公司成为全球第二家生产含血小板全血控品的供应商。40多年的发展中，R&D Systems仍持续开发各种血控品产品。  1985年，作为公司推出的第一个科研试剂产品，也是全球第一家将该产品进行商业化生产的产品，R&D Systems成功上市了TGF-beta1蛋白。作为胞外信号分子，TGF-beta1蛋白在多种细胞中进行表达，并作为胞外信号分子参与免疫功能，细胞增殖和细胞分化等生物学过程。该产品推出后，公司陆续从生物材料中纯化了几种细胞因子产品并推向市场。  天然蛋白类产品的成功推广，加速了R&D Systems在细胞因子市场的开拓。公司于1985年形成Growth Factor事业部（现Biotechnology事业部）。Biotechnology事业部的目标是生产和营销重组人细胞因子。与天然来源提取蛋白相比较，DNA重组技术生产的蛋白产品其成本更低，产量更高，完全摆脱原料的限制。1989年，Biotechnology事业部开始开发抗细胞因子的单克隆和多克隆抗体，并于1990年开发了第一个ELISA试剂盒。  2014年2月10日，R&D Systems的母公司宣布命名为Bio-Techne. Bio-Techne旗下包括R&D Systems, Novus Biologicals, BiosPacific, Tocris Bioscience, Boston Biochem和Bionostics。